Ca 125

Ca 125 is a glycoprotein found on the surface of many cells, and its levels in the blood can be measured to provide important information, particularly in the context of certain medical conditions.

Ca 125

Key Takeaways

  • Ca 125 is a protein marker primarily used to monitor ovarian cancer.
  • It is not a definitive diagnostic test for cancer, as many non-cancerous conditions can also elevate its levels.
  • Elevated levels warrant further investigation but do not automatically indicate malignancy.
  • Normal Ca 125 levels can vary, and results must always be interpreted in conjunction with a patient’s overall clinical picture.
  • The test is valuable for tracking treatment response and recurrence in diagnosed cancer patients.

What is Ca 125 and What is the Test Used For?

Ca 125 (Cancer Antigen 125) is a protein that is present in higher concentrations on the surface of ovarian cancer cells, as well as some other cancer cells and normal tissues. It is considered a tumor marker, meaning it can be found in increased amounts in the blood, urine, or body tissues of some people with cancer. However, it’s important to understand that Ca 125 is not exclusively produced by cancer cells.

The primary purpose of the Ca 125 test is to monitor the effectiveness of treatment for certain cancers, particularly ovarian cancer, and to detect recurrence after treatment. While it can be used as part of the diagnostic workup for women with symptoms suggestive of ovarian cancer, it is not recommended as a standalone screening test for the general population due to its lack of specificity. The test measures the amount of Ca 125 in a blood sample, providing a numerical value that clinicians use to guide patient management.

Interpreting Ca 125 Blood Test Results and Causes of Elevation

Understanding ca 125 blood test results explained requires careful consideration of various factors beyond just the numerical value. Results are typically reported in units per milliliter (U/mL). Generally, a level below 35 U/mL is considered within the normal range, though this can vary slightly between laboratories. However, a single elevated reading does not automatically signify cancer, nor does a normal reading rule it out. The trend of Ca 125 levels over time is often more informative than a single measurement, especially for monitoring purposes.

The normal ca 125 levels meaning is that the concentration of this protein in the blood is within the expected range for most healthy individuals. However, it’s crucial to remember that some individuals with early-stage ovarian cancer may have normal Ca 125 levels, and conversely, many non-cancerous conditions can lead to elevated levels. Therefore, Ca 125 results are always interpreted in the context of a patient’s medical history, physical examination, and other diagnostic tests, such as imaging studies or biopsies.

There are numerous causes of elevated ca 125, which can be broadly categorized into cancerous and non-cancerous conditions. This highlights why the test is not used for general population screening but is valuable in specific clinical scenarios. Non-cancerous causes are quite common and include:

  • Endometriosis
  • Uterine fibroids
  • Pelvic inflammatory disease (PID)
  • Menstruation
  • Pregnancy
  • Liver disease (e.g., cirrhosis)
  • Pancreatitis
  • Peritonitis (inflammation of the abdominal lining)
  • Benign ovarian cysts

Cancerous conditions that can cause elevated Ca 125 levels include ovarian cancer (the most common association), fallopian tube cancer, primary peritoneal cancer, and sometimes other cancers such as pancreatic, lung, breast, or colon cancer. Due to the wide range of potential causes, an elevated Ca 125 level always necessitates further medical evaluation to determine the underlying reason.

[EN] Cancer Types

Cancer Clinical Trial Options

Specialized matching specifically for oncology clinical trials and cancer care research.

Your Birthday


By filling out this form, you’re consenting only to release your medical records. You’re not agreeing to participate in clinical trials yet.